Thursday, June 13, 2024

Cisco Earnings, Revenue Outlook Top Estimates Amid Restructuring Plan

Must read

Cisco Systems (CSCO) on Wednesday reported fiscal first-quarter earnings and revenue that topped consensus estimates. CSCO stock rose as the computer networking giant also announced a restructuring plan and gave a revenue outlook that was above views.


Cisco earnings for the quarter ended Oct. 29 rose 5% year over year to 86 cents a share, topping Wall Street’s target. The company said revenue increased 6% to $13.6 billion.

Analysts polled by FactSet had estimated Cisco earnings of 84 cents a share on revenue of $13.31 billion.

For the current January-ending quarter, Cisco said it expects profit of 85 cents a share, in line with estimates. Cisco projected revenue growth of 5.5% at the midpoint of its guidance, above estimates for 4% sales growth.

CSCO Stock: Restructuring Plan Announced

In addition, Cisco announced a restructuring plan. The company said it will recognize pretax charges of about $600 million consisting of severance and other one-time termination benefits, real estate-related charges and other costs. Cisco expects to recognize about $300 million of the charges in fiscal Q2.

“We delivered strong results in Q1 and continued to make progress on our business transformation,” Chief Financial Officer Scott Herren said in the earnings release. “Our annualized recurring revenue increased to more than $23 billion, with product ARR growing 12%.”

Cisco stock climbed nearly 4% to 46.15 in extended trading on the stock market today.

Heading into the Cisco earnings report, the company owned a Relative Strength Rating of 42 out of a best-possible 99, according to IBD Stock Checkup. CSCO stock had declined 30% in 2022.

In addition, CSCO stock has shifted away from its core business of selling network switches and routers. With acquisitions, Cisco has aimed to increase revenue from software and services.

Follow Reinhardt Krause on Twitter @reinhardtk_tech for updates on 5G wireless, artificial intelligence, cybersecurity and cloud computing.


Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm

IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today

Learn How To Time The Market With IBD’s ETF Market Strategy

How To Use The 10-Week Moving Average For Buying And Selling

IBD Live: A New Tool For Daily Stock Market Analysis

More articles

Latest article